Collecting real-world data on the management of metastatic colorectal cancer (mCRC)
The purpose of PROMETCO is to provide real-world data on overall survival, treatment patterns, associated effectiveness and safety, and impact on patients with mCRC throughout the continuum of care1
CRC is a major public health burden2,3
- 1.85 million new cases in 2018
- 881,000 deaths in 2018
- <10% survival rate in patients with stage IV CRC
Latest news
Presented June 26–29 2024
We have released a poster on overall and progression-free survival according to first and second-line treatment regimen, presented at ESMO-GI 2024.
View the poster here!
Final recruitment numbers
18
Participating
countries
96
Investigational sites
96 recruiting
738
Patients enrolled
ARG: Argentina, AUT: Austria, BEL: Belgium, CHE: Switzerland, CZE: Czech Republic, DEU: Germany, ESP: Spain, FRA: France, GRE: Greece, HRV: Croatia, HUN: Hungary, IRL: Ireland, ITA: Italy, NLD: Netherlands, PRT: Portugal, SVN: Slovenia, SWE: Sweden, UK: United Kingdom
Local publications
PROMETCO gives the opportunity to provide local information on outcomes. Read the latest publications from some of our participating countries:
Upcoming congresses
The Servier team will be attending the following congresses:
Come and meet the team to discuss any questions you have about PROMETCO.
Why PROMETCO
PROMETCO rationale
Advances in treatment of mCRC in the past 15 years have improved patient survival to ~30 months based on data from RCTs4
Data from prospective real-world studies are lacking
PROMETCO aims to address this gap
PROMETCO study objectives
Study objectives are to describe the following for mCRC patients in a real-world setting:
Overall survival
Treatment patterns for mCRC throughout the continuum of care
Effectiveness/safety of treatments in a real-world setting
Reasons for therapy discontinuations and choice of subsequent treatment
Adherence to national and ESMO guidelines
Healthcare resource utilization
Patient-reported outcomes
